Watch the 30-day go-shop period ending ~Nov 5, 2026 for any superior proposals. The Series A preferred holder conversion/waiver condition and preferred stock acquisition by SRX are key gating items. Deal close expected shortly after go-shop end if conditions met.
Price Chart
Executive Summary
SRX Global Inc. (SRXH) entered into a Stock Purchase Agreement to acquire CERo Therapeutics, Inc., a clinical-stage biopharmaceutical company, from CERo Therapeutics Holdings, Inc. The total consideration includes ~$1M in SRXH common stock, forgiveness of an $8.25M secured note, and assumption of ~$1.56M in liabilities. The deal includes a 30-day go-shop period and is subject to closing conditions including preferred stock transactions and Series A preferred holder consents.
Key Financial Metrics
Key Facts
- SRX Global Inc. to acquire CERo Therapeutics, Inc. (clinical-stage biopharma, lead candidate CER-1236) from CERo Therapeutics Holdings
- Consideration: ~$1M in SRXH common stock (price based on lower of closing price or 20-day VWAP), forgiveness of $8,249,643.77 outstanding secured note, and assumption of ~$1,562,000 in liabilities
- 30-day go-shop period allows Holdings to solicit superior proposals; $750,000 termination fee payable by Holdings in certain scenarios
- Closing conditioned on SRX acquiring Holdings' Series C/D/E preferred stock and Series A preferred holders converting or waiving rights
- 180-day lock-up on stock consideration for Holdings; registration rights agreement to be entered at closing
- No financing condition for SRX; buyer represents it will have funds available at closing
Financial Impact
Total consideration: ~$1M in SRXH stock + $8.25M debt forgiveness + ~$1.56M assumed liabilities = ~$10.8M total; SRXH has 20,184,391 shares outstanding pre-deal
Risk Factors
- Superior proposal could emerge during go-shop period, terminating this deal
- Series A preferred holders may not convert or waive rights as required for closing
- SRX's ability to acquire Holdings' preferred stock is a condition to closing
- CERo is a clinical-stage biopharma with no approved products; lead candidate CER-1236; regulatory/commercial risk
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-046085 |
| Document: form8-k.htm | 0001493152-26-046085 |
| Document: 0001493152-26-046085-index-headers.html | 0001493152-26-046085 |
| Document: 0001493152-26-046085-index.html | 0001493152-26-046085 |
| Document: 0001493152-26-046085.txt | 0001493152-26-046085 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | 8-K | $1.49 $1.29 | ▼ −13.42% | ▼ −12.44% | $1.07 (−28.19%) |
Oct 6, 2026 20d ago | 8-K | $1.49 $1.29 | ▼ −13.42% | ▼ −12.44% | $1.07 (−28.19%) |
Sep 24, 2026 4w ago | Press Release | $1.73 $1.61 | ▼ −6.94% | ▼ −6.52% | $1.07 (−38.15%) |
Sep 9, 2026 6w ago | 8-K | $1.51 $1.60 | ▲ +5.96% | ▲ +6.62% | $1.07 (−29.14%) |
Sep 2, 2026 7w ago | 8-K | $1.56 $1.59 | ▲ +1.92% | ▲ +3.07% | $1.07 (−31.41%) |
Aug 28, 2026 8w ago | 8-K | $1.68 $1.59 | ▲ +5.65% | ▲ +5.51% | $1.07 (+36.31%) |
Aug 19, 2026 9w ago | 8-K | $1.87 $1.84 | ▼ −1.60% | ▼ −1.22% | $1.07 (−42.78%) |
Aug 4, 2026 12w ago | Press Release | $1.37 $1.84 | ▲ +34.31% | ▲ +34.41% | $1.07 (−21.90%) |
Aug 3, 2026 12w ago | Press Release | $1.44 $1.73 | ▲ +20.14% | ▲ +18.11% | $1.07 (−25.69%) |
Jul 30, 2026 12w ago | Press Release | $1.48 $1.43 | ▼ −3.38% | ▼ −7.00% | $1.07 (−27.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers